Is ICU Medical (ICUI) overvalued or fairly valued?

MarketChacha shows ICU Medical's valuation in context — a trailing P/E of about 85.1, a forward P/E of about 17.0, a price-to-book of about 1.9 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of ICU Medical (ICUI)?

ICU Medical last traded at $158.34 (-0.3% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

ICU Medical

ICUI · NYSE · Healthcare · United States

$158.34-0.3%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:25 PM

Snapshot

TickerICUI

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees13,000

HeadquartersSan Clemente, United States

Market cap$4.0B

P/E (TTM)85.1

P/B1.9

Volume86K

Websitewww.icumed.com

Filings tracked3

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Profile as reported by Yahoo Finance.

Who owns it

Insiders1.9%
Institutions98.1%
Public & other0.0%

385 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.14.44%
Janus Henderson Group PLC10.71%
Vanguard Portfolio Management LLC5.75%
Fuller & Thaler Asset Management Inc.4.88%
Vanguard Capital Management LLC4.45%
Dimensional Fund Advisors LP3.94%
State Street Corporation3.87%
Schroder Investment Management Group2.81%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Latest ROE of 0.0% is on the low side — the business earns a modest return on shareholder capital.

Return on equity0.0%

Latest ROE of 0.0% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $551.8M · EPS 2.08

Est. earnings growth +2.6%

Next fiscal year

Rev $2.3B · EPS 9.34

Est. earnings growth +14.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$107.0052-wk range$162.85

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$4.0B

Day change

-0.3%

P/E (TTM)

85.1

Fwd P/E

17.0

P/B

1.9

Beta

0.76

ROE

0.0%

EPS (FY2025)

0.03

Net profit (FY2025)

$732,000

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about ICUI

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Net profit	EPS	ROE
FY2025	$732,000	0.03	0.0%
FY2024	$-117.7M	-4.83	-6.0%
FY2023	$-29.7M	-1.23	-1.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$530.2M	$30.1M	1.20	5.7%
2025Q3	$537.0M	$-3.4M	-0.14	-0.6%
2025Q2	$548.9M	$35.3M	1.43	6.4%
2025Q1	$604.7M	$-15.5M	-0.63	-2.6%
2024Q3	$589.1M	$-33.0M	-1.35	-5.6%
2024Q2	$596.5M	$-21.4M	-0.88	-3.6%
2024Q1	$566.7M	$-39.5M	-1.63	-7.0%
2023Q3	$553.3M	$7.2M	0.30	1.3%
2023Q2	$549.3M	$-9.9M	-0.41	-1.8%
2023Q1	$568.6M	$-9.8M	-0.41	-1.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/18/2026material
8-K — Results of operations, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.